Setmelanotide: Imcivree, drug for rare genetic obesity

What this is

Setmelanotide (brand name Imcivree; development code RM-493) is a daily subcutaneous injection that treats a small group of rare obesity conditions in which the brain's "you're full" signal is broken. It mimics a natural fullness hormone called α-melanocyte-stimulating hormone (α-MSH) by activating the melanocortin-4 receptor (MC4R) in the hypothalamus, restoring the satiety signal that affected patients cannot produce on their own.

The drug is FDA- and EMA-approved, but only for patients in whom that pathway is demonstrably disrupted: genetic POMC, PCSK1, or LEPR deficiency; Bardet-Biedl syndrome (BBS); and — as of March 2026 — acquired hypothalamic obesity (Rhythm Pharmaceuticals announcement, March 19, 2026). It is not approved for, and does not work well in, common polygenic obesity. As of March 2026, Imcivree is the first and only approved therapy for acquired hypothalamic obesity, a condition estimated to affect roughly 10,000 patients in the US.

Chemically, setmelanotide is a cyclic octapeptide with an N-terminal acetyl cap, a C-terminal amide, an intramolecular disulfide bridge between its two cysteine residues, and D-amino-acid substitutions — features essential to its receptor selectivity and half-life but not visible in the stored 8-letter sequence (Markham, Drugs 2021).

History

The molecule originated at Ipsen as BIM-22493 / IRC-022493 and was advanced by Rhythm Pharmaceuticals, a Boston biotech founded specifically to develop precision treatments for rare melanocortin-pathway obesity disorders. Its design — a cyclic octapeptide with high MC4R selectivity relative to first-generation melanocortin tool compounds such as Melanotan II — was driven by decades of academic genetics work establishing that loss-of-function mutations in POMC, PCSK1, LEPR, and MC4R itself produce severe early-onset obesity by disrupting the leptin-melanocortin satiety pathway in the hypothalamus.

The therapeutic hypothesis was straightforward: in patients whose upstream signaling is broken but whose downstream MC4R is intact, providing an exogenous MC4R agonist could restore the missing "fullness" signal. Early proof-of-concept results appeared in a POMC-deficient patient (Kühnen and colleagues, NEJM 2016), followed by durable weight loss in leptin-receptor-deficient patients (Clément and colleagues, Nature Medicine 2018) and in MC4R-pathway populations (Collet and colleagues, Molecular Metabolism 2017).

Pivotal Phase 3 single-arm trials in POMC, PCSK1, and LEPR deficiency formed the basis for the November 2020 FDA approval of Imcivree (Markham, Drugs 2021) — a notable approval because the indicated population is vanishingly small and because the trial design used historical-control framing rather than randomized comparison, appropriate to the rarity of the disease. In June 2022, FDA expanded the indication to include Bardet-Biedl syndrome following a randomized Phase 3 trial (Haqq and colleagues, Lancet Diabetes & Endocrinology 2022). A pediatric extension to ages 2–5 followed in 2024, supported by the VENTURE trial (Argente and colleagues, Lancet Diabetes & Endocrinology 2025).

On March 19, 2026, the FDA approved setmelanotide for a fundamentally different population: acquired hypothalamic obesity in adults and pediatric patients aged 4 and older. Unlike the prior monogenic indications, acquired hypothalamic obesity is not a germline disease — it results from injury to the hypothalamic appetite-regulation centers, most often after surgery or radiation for childhood craniopharyngioma (Rhythm Pharmaceuticals, March 19, 2026).

What it does

In patients whose leptin-POMC-MC4R satiety pathway is disrupted upstream — by loss-of-function mutations or by hypothalamic injury — setmelanotide supplies the missing signal at MC4R itself. Clinically, this translates to a reduction in hyperphagia (the relentless hunger characteristic of these conditions), reduced food intake, and weight loss that accrues over months.

In adults without confirmed MC4R-pathway disruption, an earlier crossover study showed setmelanotide increased resting energy expenditure (Chen and colleagues, J Clin Endocrinol Metab 2015), but a comparable weight-loss effect was never replicated in unselected polygenic obesity — a contrast that the field continues to discuss (Prindle and colleagues, Frontiers in Endocrinology 2026).

Evidence

• Human: Strong for the approved indications. In Phase 3 single-arm trials, patients with POMC/PCSK1 or LEPR deficiency achieved approximately 25% body-weight reduction (POMC) and approximately 12% (LEPR) at 12 months (Clément and colleagues, Lancet Diabetes & Endocrinology 2020). In the Phase 3 BBS randomized trial, patients lost approximately 8% body weight at 52 weeks (Haqq and colleagues, Lancet Diabetes & Endocrinology 2022); quality-of-life improvements were documented in parallel (Forsythe and colleagues, Orphanet Journal of Rare Diseases 2023). The Phase 3 TRANSCEND trial (n=142) in acquired hypothalamic obesity reported a −15.8% BMI change on setmelanotide versus +2.6% on placebo at 52 weeks — an 18.4% placebo-adjusted effect, and the basis for the March 2026 FDA approval (Rhythm Pharmaceuticals, March 19, 2026). A Phase 2 open-label trial in acquired hypothalamic obesity preceded TRANSCEND (Lancet Diabetes & Endocrinology 2024). A systematic review and meta-analysis pooled efficacy and safety across published trials (Ferraz Barbosa and colleagues, Journal of Personalized Medicine 2023).
• Animal: Extensive. MC4R biology is one of the best-characterized appetite-regulation systems in obesity research; setmelanotide pharmacology was profiled in non-human primates before entering human trials.
• In vitro: Receptor-binding and selectivity studies establish setmelanotide as a high-affinity MC4R agonist with greater potency than native α-MSH and engineered selectivity over related melanocortin receptors. Continued structure–activity work is refining the chemotype (Bioorganic Chemistry 2025).

Myths and misconceptions

• "Setmelanotide is a general-purpose weight-loss drug like semaglutide." — It is not. FDA approval is restricted to confirmed POMC, PCSK1, or LEPR deficiency, Bardet-Biedl syndrome, and acquired hypothalamic obesity. Genetic testing (or documented hypothalamic injury) is required before prescribing. In unselected obesity, the magnitude of effect seen in monogenic populations does not replicate, and the side-effect profile is not justified by benefit (Prindle and colleagues, Frontiers in Endocrinology 2026).
• "Setmelanotide and Melanotan II are basically the same drug because they're both melanocortin agonists." — They share MC4R-binding pharmacology but differ substantially. Setmelanotide is an FDA-approved cyclic octapeptide engineered for receptor selectivity, with a defined therapeutic window and a real safety database. Melanotan II (/card/pep-00020) is a research-chemical cyclic heptapeptide with much broader receptor activity and no approved human indication.
• "Skin darkening on setmelanotide means the drug is harming the patient." — Hyperpigmentation is an expected pharmacological effect from MC1R cross-activation on melanocytes, not a toxicity signal. It largely fades after discontinuation. The clinically important monitoring is dermatologic surveillance for new or changing nevi, not the pigmentation itself (Clément and colleagues, Obesity Facts 2021).
• "Treatment-resistant obesity probably means you have one of these genetic conditions." — Combined POMC, PCSK1, LEPR, and BBS-related obesity is rare — low thousands of patients globally. The vast majority of severe obesity is polygenic. Genetic testing should be guided by clinical phenotype (very early onset, hyperphagia, syndromic features), not by treatment resistance alone.

Known effects

• Weight reduction in monogenic POMC, PCSK1, or LEPR deficiency — FDA-approved (Phase 3 single-arm)
• Weight reduction in Bardet-Biedl syndrome — FDA-approved (Phase 3 randomized trial)
• BMI reduction in acquired hypothalamic obesity — FDA-approved (Phase 3 randomized trial, March 2026)
• Reduction in hyperphagia — documented across Phase 3 trials in monogenic and BBS populations
• Quality-of-life improvements — documented in Phase 3 trials in BBS and in LEPR/POMC populations (Forsythe and colleagues, Orphanet J Rare Dis 2023)
• Increased resting energy expenditure in unselected obese adults — observed in an early crossover study (Chen and colleagues, J Clin Endocrinol Metab 2015); did not translate into a polygenic-obesity weight-loss indication
• MASLD and kidney-function signals in BBS — early real-world data suggest potential metabolic benefits in BBS beyond weight (Hühne and colleagues, J Clin Endocrinol Metab 2026)

Safety signals

• Skin hyperpigmentation — very common; an expected pharmacological consequence of MC1R cross-activation on melanocytes; affects skin, lips, gums, hair, and existing nevi; largely reversible after discontinuation. A baseline full-body skin exam is recommended in clinical practice, with ongoing dermatologic monitoring for new or changing pigmented lesions (Clément and colleagues, Obesity Facts 2021).
• Injection-site reactions — common across clinical trials.
• Spontaneous penile erections and other sexual adverse events — reported in both sexes, reflecting central melanocortin activity overlapping with the bremelanotide arousal pathway (Markham, Drugs 2021).
• Depression and suicidal ideation — a labeled warning. Mood is monitored during dose initiation and changes (Markham, Drugs 2021).
• Small increases in heart rate and blood pressure — associated with chronic MC4R activation; long-term cardiovascular endpoint data are not established.
• Long-term cardiovascular, neuropsychiatric, and pediatric-developmental outcomes — remain under active post-market surveillance. Approval down to age 2 (monogenic) and age 4 (acquired HO) rests on relatively limited-duration data; ongoing observation of growth, puberty, bone development, and neurodevelopment is required (Argente and colleagues, Lancet Diabetes & Endocrinology 2025).

Across published Phase 3 acquired-hypothalamic-obesity data, the most common adverse events affecting more than 20% of participants were skin hyperpigmentation, nausea, vomiting, and headache (Rhythm Pharmaceuticals, March 19, 2026).

Regulatory status

• US (FDA): Approved prescription drug (specialty, restricted distribution). Initial approval November 2020 (POMC/PCSK1/LEPR deficiency); expanded June 2022 (Bardet-Biedl syndrome); 2024 (ages 2–5 for monogenic indications); March 19, 2026 (acquired hypothalamic obesity, ages 4+). Prescription access requires confirmed genetic testing or documented hypothalamic injury (Markham, Drugs 2021; Rhythm Pharmaceuticals, March 19, 2026).
• EU (EMA): Approved (Imcivree) December 2021 for monogenic obesity and Bardet-Biedl syndrome. CHMP positive opinion for acquired hypothalamic obesity issued March 2026; formal European Commission decision expected to follow.
• WADA: Not specifically named on the Prohibited List but captured under S0 ("substances not approved for human therapeutic use by any governmental health authority") for use outside the specific FDA/EMA-approved rare-disease indications.
• US controlled-substance schedule: Not scheduled.

Mechanism

Setmelanotide is a cyclic octapeptide that selectively agonizes the melanocortin-4 receptor (MC4R), a Gαs-coupled GPCR expressed in the hypothalamic paraventricular nucleus and other appetite-regulatory regions. The leptin-POMC-MC4R signaling cascade operates as follows: leptin binding to LEPR on POMC neurons drives production of α-melanocyte-stimulating hormone (α-MSH); α-MSH binds MC4R; MC4R activation reduces appetite and increases energy expenditure via downstream sympathetic and central pathways. In POMC deficiency, α-MSH is not produced. In LEPR deficiency, leptin cannot signal POMC neurons. In Bardet-Biedl syndrome, ciliary dysfunction disrupts hypothalamic signaling. In acquired hypothalamic obesity, the upstream circuitry itself is injured. In each case, setmelanotide bypasses the broken upstream step by directly engaging MC4R (Clément and colleagues, Nature Medicine 2018; Qamar and colleagues, touchREVIEWS in Endocrinology 2024).

Structurally, the molecule is closed by a disulfide bridge between its two cysteine residues, with an N-terminal acetyl cap, a C-terminal amide, and D-amino-acid substitutions that confer protease resistance and contribute to a much longer plasma half-life than that of native α-MSH. These features and the receptor-selectivity profile distinguish it from broader-spectrum melanocortin agonists such as Melanotan II (/card/pep-00020) and from the MC1R-selective agonist afamelanotide (/card/pep-10666).

Setmelanotide additionally activates NFAT signaling at MC4R, a feature reported to restore function for selected MC4R variants that lose canonical Gαs-coupling (Clément and colleagues, Nature Medicine 2018). Skin hyperpigmentation is an expected pharmacological consequence of cross-reactivity with MC1R on melanocytes; sexual adverse events arise from MC4R activation in central circuits that overlap with the bremelanotide (/card/pep-10871) arousal pathway.

Open questions

• Long-term cardiovascular and metabolic outcomes — chronic MC4R activation produces small increases in heart rate and blood pressure; whether these translate to long-term cardiovascular risk in chronically treated patients has not been established in dedicated endpoint trials.
• Mechanism of the neuropsychiatric warning — the labeled depression and suicidal-ideation signal has not been mechanistically characterized; predictors of which patients are at higher risk are not defined.
• Pediatric long-term developmental safety — approval extends to ages 2–5 (monogenic) and ages 4+ (acquired hypothalamic obesity) on the basis of relatively limited-duration trial data; long-term effects on growth, puberty, bone development, and neurodevelopment remain under surveillance.
• Polygenic-obesity efficacy — setmelanotide has been studied almost exclusively in monogenic and BBS populations; whether MC4R agonism produces meaningful weight loss in the much larger common-obesity population is unresolved, with mixed signals from earlier exploratory work (Prindle and colleagues, Frontiers in Endocrinology 2026).
• Combination with incretin agonists — mechanistic complementarity with semaglutide (/card/pep-00016), tirzepatide (/card/pep-00017), or retatrutide (/card/pep-00018) is described as plausible, but has not been evaluated in adequately powered trials.
• Real-world acquired-hypothalamic-obesity response variability — the TRANSCEND trial enrolled a population with a defined hypothalamic-injury phenotype and high baseline BMI; how the effect translates across milder phenotypes, different injury etiologies (tumor vs. radiation vs. surgical), and longer time horizons is still accruing.

Related peptides

• Melanotan II — first-generation broad-spectrum cyclic melanocortin agonist; the receptor-selectivity contrast that motivated setmelanotide's design.
• Afamelanotide / Melanotan I — MC1R-selective melanocortin agonist; approved for erythropoietic protoporphyria; clarifies the MC1R-driven pigmentation pharmacology that setmelanotide partially shares.
• PT-141 / Bremelanotide — melanocortin agonist approved for hypoactive sexual desire disorder; overlaps with the central MC4R arousal pharmacology that drives setmelanotide's sexual adverse events.
• Semaglutide, Tirzepatide, Retatrutide — incretin-pathway anti-obesity agents that act through a completely different mechanism; the comparator class for general (polygenic) obesity pharmacology.